Pomalyst (pomalidomide) and Thalomid (thalidomide) - Assessing the potential risk of progressive multifocal leukoencephalopathy
A summary safety review (SSR) regarding Pomalyst (pomalidomide) and Thalomid (thalidomide) and the poten...
Read moreResearch & Access Updates
Great news for ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation program, co-lead by Annette Hay
The Canadian Cancer Trials Group (CCTG) and Queen’s researcher Annette Hay (Medicine) and Jonathan Bramso...
Read moreCancer System Quality Index by Cancer Care Ontario
This year, for the first time, the publication of the annual Cancer System Quality Index by Cancer Care O...
Read moreNew Canadian pharmaceutical company brings novel cancer therapies to market
(Toronto, Ont.) January 27, 2021 ¬– FORUS Therapeutics launches today, bringing a new pharmaceutical comp...
Read moreLifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers
Farmers have a higher incidence of multiple myeloma, and there is suggestive evidence of an elevated prev...
Read moreReal‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma
Extract o the report: Bortezomib‐containing regimens (BCRs) represented standard, first‐line therapy f...
Read more